Cerebral venous thrombosis in Behcet's disease. A report on 24 cases

Oumerzouk, Jawad; Klevor, Raymond; Badr, Slioui; Chraa, Mohamed; Louhab, Nissrine; Kissani, Najib

doi:10.1016/j.neurol.2021.05.008

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that the frequency of arterial lesions ranges from 1-33.5%. [10][11][12] In the current study, the frequency was 18.5% (12/65). All 6 patients with hypertension suffered from stage 2 hypertension and hypokalaemia caused by the increased production of renin due to stenosis of the renal arteries.…”

Section: Treatment and Follow-upsupporting

confidence: 44%

“…It is concluded that thrombosis in BD is mainly mediated by in ammation and that immunosuppressive therapy should be the core of treatment, including immunosuppressive drugs. [15,16,17] Anticoagulant therapy may signi cantly increase the risk of aneurysm rupture and fatal hemorrhage, and immunosuppressive therapy is important for patients with thrombosis. [18,19] Hence, patients with venous thrombosis should undergo relevant examinations to detect the existence of pulmonary artery aneurysms.…”

Section: Treatment and Follow-upmentioning

confidence: 99%

See 1 more Smart Citation

Hypertension as a prominent manifestation in pediatric Behcet's disease

Wang,

Zhou,

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: Hypertension caused by vascular Behcet’s disease(BD) is an important prognostic factor of pediatric BD. However, much less is known about it’s clinical features. The objective of this study is to investigate the clinical characteristics of pediatric BD complicated by hypertension. Methods: A retrospective study was carried out in pediatric BD complicated by hypertension hospitalized at the Children’s Hospital Capital Institute of Pediatrics from Jan 2009 to Dec 2022. Results: Of 65 BD patients, 6 (9.2%) were complicated by hypertension, 4 patients were female, and the median ages of onset and diagnosis were9.8 years and 11.3 years, respectively. Five of the 6 patients with hypertension had right renal artery involvement,and all of them were treated with glucocorticoids and immunosuppressants. Four patients were treated with biological agents. One patient with severe renal artery stenosis received vascular interventional therapy, but it failed. After 3-6 years of follow-up, five patients were found to have renal atrophy, and one patient was in stable condition. Conclusion: Hypertension in pediatric BD is mainly caused by renal artery involvement. Early recognition and treatment of vascular involvement in BD is important to prevent poor prognosis.

show abstract

Section: Treatment and Follow-upsupporting

confidence: 44%

Section: Treatment and Follow-upmentioning

confidence: 99%

Hypertension as a prominent manifestation in pediatric Behcet's disease

Wang,

Zhou,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Small sample size and unblinded measurements were the main limitations of the study. A study including 24 BS patients with cerebral venous sinus thrombosis showed a high prevalence of deep CVST (n=18; 75%) confirmed by angiographic demonstration of basal vein of Rosenthal thrombosis (75). The results need to be reproduced in a larger cohort and in different ethnic populations.…”

Section: Nervous System Involvementmentioning

confidence: 94%

Behçet's syndrome: one year in review 2022

Hatemi

Seyahi

Fresko

et al. 2022

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

This review highlights publications on different aspects of Behçet's syndrome (BS) that appeared in 2021 and provides a critical view. These publications include works on the epidemiology of BS across different continents, newly developed instruments to assess damage in BS, studies highlighting the immunopathogenesis, genetics and epigenetic factors, histopathology of the pathergy lesion, clinical and imaging aspects of vascular involvement, and safety and efficacy of therapeutic agents including tocilizumab, apremilast and direct oral anticoagulants.

show abstract